Clinical Trial

A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to study the impact of Dyanavel on co-occuring fatigue in adults with Attention Deficit/Hyperactivity Disorder. The main question it aims to answer is whether Dyanavel XR leads to a statistically significant reduction in fatigue compared to placebo, as measured by the Fatigue Symptom Inventory.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-31; most recent amendment 2024-11-18.
Status change: Not Yet Recruiting → Recruiting 2024-11-18
Trial Details
NCT Number NCT06248229
Lead Sponsor Rochester Center for Behavioral Medicine
Conditions Fatigue, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
Enrollment 50 participants
Start Date 2024-09-01
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-21